Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Freeline Bags Alnylam's Heggie As CEO

Hemophilia B Gene Therapy Advances

Executive Summary

Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.

You may also be interested in...



UniQure Aiming To Be First With Hemophilia B Gene Therapy

The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.

UniQure Has High HOPE For Hemophilia B Gene Therapy

The Dutch company's update on AMT-061 and the initiation of a pivotal trial called HOPE-B of around 50 patients could put the product in pole position to be the first gene therapy on the market for the severe orphan blood clotting disorder.

£88m Series B For Syncona-backed Freeline To Advance Liver Gene Therapy Focus

Chairman says Freeline's series B financing gives it adequate funds for Phase I/II trials in hemophilia B and entry into Fabry disease.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel